Biomarkers as Surrogate End Points in Heart Failure Trials

Heart Failure Clinics

Volumn 7, Issue 4, 2011, Pages 501-507

  Felker, G Michael ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Clinical trials; Heart failure; Natriuretic peptides; Surrogate end points

Indexed keywords

ALISKIREN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; BUCINDOLOL; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; HORMONE PRECURSOR; HYDRALAZINE; ISOSORBIDE DINITRATE; LEVOSIMENDAN; MILRINONE; NESIRITIDE; SPIRONOLACTONE; TROPONIN; VALSARTAN;

ACUTE CORONARY SYNDROME; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FUNCTIONAL STATUS; HEART EJECTION FRACTION; HEART FAILURE; HEART HEMODYNAMICS; HEART VENTRICLE FUNCTION; HEART VENTRICLE VOLUME; HUMAN; LABORATORY TEST; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; REVIEW; STUDY DESIGN; SURROGATE END POINT; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HEART FAILURE; HUMANS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 80052918637     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.06.001     Document Type: Review

References (52)

1. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119(3):e21-e181.
2. McMurray J.J., Teerlink J.R., Cotter G., et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007, 298(17):2009-2019.
3. Mebazaa A., Nieminen M.S., Packer M., et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007, 297(17):1883-1891.
4. Metra M., Eichhorn E., Abraham W.T., et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J 2009, 30(24):3015-3026.
5. Fox K., Ford I., Steg P.G., et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372(9641):807-816.
6. Konstam M.A., Gheorghiade M., Burnett J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007, 297(12):1319-1331.
7. Felker G.M., Pang P.S., Adams K.F., et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail 2010, 3(2):314-325.
8. Allen L.A., Hernandez A.F., O'Connor C.M., et al. End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol 2009, 53(24):2248-2258.
9. Atkinson A.J., Colburn W.A., DeGruttola V.G., et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69(3):89-95.
10. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358(20):2148-2159.
11. Felker G.M., Petersen J.W., Mark D.B. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ 2006, 175(6):611-617.
12. Miller W.L., Hartman K.A., Burritt M.F., et al. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2009, 54(18):1715-1721.
13. Januzzi J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007, 50(7):607-613.
14. van Kimmenade R.R., Januzzi J.L., Ellinor P.T., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006, 48(6):1217-1224.
15. Kempf T., von Haehling S., Peter T., et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007, 50(11):1054-1060.
16. Maisel A., Mueller C., Nowak R., et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010, 55(19):2062-2076.
17. Thygesen K., Alpert J.S., White H.D., et al. Universal definition of myocardial infarction. Circulation 2007, 116(22):2634-2653.
18. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998, 339(7):436-443.
19. Anand I.S., Florea V.G., Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol 2002, 39(9):1414-1421.
20. Cleland J.G., McMurray J.J., Kjekshus J., et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009, 54(20):1850-1859.
21. Januzzi J.L., Sakhuja R., O'Donoghue M., et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the Emergency Department. Arch Intern Med 2006, 166(3):315-320.
22. Cleland J.G., Taylor J., Tendera M. Prognosis in heart failure with a normal ejection fraction. N Engl J Med 2007, 357(8):829-830.
23. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004, 350(7):655-663.
24. Masson S., Latini R., Anand I.S., et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006, 52(8):1528-1538.
25. Logeart D., Thabut G., Jourdain P., et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004, 43(4):635-641.
26. Bettencourt P., Azevedo A., Pimenta J., et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004, 110(15):2168-2174.
27. Metra M., Nodari S., Parrinello G., et al. The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. Eur J Heart Fail 2007, 9(8):776-786.
28. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003, 107(9):1278-1283.
29. Masson S., Latini R., Anand I.S., et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008, 52(12):997-1003.
30. Latini R., Masson S., Wong M., et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006, 119(1):70.
31. McKelvie R.S., Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: the RESOLVD Pilot Study Investigators. Circulation 1999, 100(10):1056-1064.
32. Latini R., Masson S., Anand I., et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002, 106(19):2454-2458.
33. Frantz R.P., Olson L.J., Grill D., et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J 2005, 149(3):541-547.
34. Rousseau M.F., Gurné O., Duprez D., et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 2002, 40(9):1596-1601.
35. Fruhwald F.M., Fahrleitner-Pammer A., Berger R., et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 2007, 28(13):1592-1597.
36. Cohn J.N., Tam S.W., Anand I.S., et al. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail 2007, 13(5):331-339.
37. Frantz R.P., Lowes B.D., Grayburn P.A., et al. Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST). J Card Fail 2007, 13(6):437-444.
38. The Beta-Blocker Evaluation of Survival Trial Investigators A trial of the beta-blocker bucindolol in patients with advanced heart failure. N Engl J Med 2001, 344:1659-1667.
39. Cleland J.G., Freemantle N., Coletta A.P., et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006, 8:105-110.
40. Cohen-Solal A., Logeart D., Huang B., et al. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol 2009, 53(25):2343-2348.
41. Gheorghiade M., Pang P.S. Are BNP changes during hospitalization for heart failure a reliable surrogate for predicting the effects of therapies on post-discharge mortality?. J Am Coll Cardiol 2009, 53(25):2349-2352.
42. McMurray J.J.V., Pitt B., Latini R., et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008, 1(1):17-24.
43. Cuffe M.S., Califf R.M., Adams K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287:1541-1547.
44. Sackner-Bernstein J.D., Kowalski M., Fox M., et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005, 293(15):1900-1905.
45. Sackner-Bernstein J.D., Skopicki H.A., Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111(12):1487-1491.
46. Horwich T.B., Patel J., MacLellan W.R., et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003, 108(7):833-838.
47. Peacock W.F., De Marco T., Fonarow G.C., et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008, 358(20):2117-2126.
48. Del Carlo C.H., Pereira-Barretto A.C., Cassaro-Strunz C., et al. Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure. J Card Fail 2004, 10(1):43-48.
49. Miller W.L., Hartman K.A., Burritt M.F., et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation 2007, 116(3):249-257.
50. Latini R., Masson S., Anand I.S., et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007, 116(11):1242-1249.
51. Berridge B.R., Pettit S., Walker D.B., et al. A translational approach to detecting drug-induced cardiac injury with cardiac troponins: consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute. Am Heart J 2009, 158(1):21-29.
52. Gheorghiade M., Gattis Stough W., Adams K.F., et al. The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). Am J Cardiol 2005, 96(6A):18G-25G.